Home › Critical Illness › NCT07643467

Fluorescent Probe for Assessment of Renal Elimination

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

* 18-65 years old
* critically ill or acutely ill hospitalized patients admitted to the intensive care unit
* Stable/normal renal function

Exclusion Criteria:

* Prisoners
* Pregnant women
* Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr \> 1.5x baseline)

About the study

Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.

What is being tested

• Relmapirazin (drug)
• Iohexol (drug)
• Medibeacon tGFR monitor (device)
• Urine creatinine clearance collection (diagnostic test)

Sponsor: Aaron Cook · Participants: 200 · Started: Sep 1, 2026

Contact the study team

• Aaron Cook, PharmD · Phone: 18592578444

Official record on ClinicalTrials.gov — NCT07643467

Locations in the U.S.

Conditions

• Critical Illness

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.